EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer

Michael J. Levy, Steven Robert Alberts, William R. Bamlet, Patrick A. Burch, Michael B. Farnell, Ferga C. Gleeson, Michael Haddock, Michael L. Kendrick, Ann L Oberg, Gloria M Petersen, Naoki Takahashi, Suresh T Chari

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background and Aims: Among the greatest hurdles to pancreatic cancer (PC) therapy is the limited tissue penetration of systemic chemotherapy because of tumor desmoplasia. The primary study aim was to determine the toxicity profile of EUS-guided fine-needle injection (EUS-FNI) with gemcitabine. Secondary endpoints included the ability to disease downstage leading to an R0 resection and overall survival (OS) at 6 months, 12 months, and 5 years after therapy. Methods: In a prospective study from a tertiary referral center, gemcitabine (38 mg/mL) EUS-FNI was performed in patients with PC before conventional therapy. Initial and delayed adverse events (AEs) were assessed within 72 hours and 4 to 14 days after EUS-FNI, respectively. Patients were followed for ≥5 years or until death. Results: Thirty-six patients with stage II (n = 3), stage III (n = 20), or stage IV (n = 13) disease underwent gemcitabine EUS-FNI with 2.5 mL (.7-7.0 mg) total volume of injectate per patient. There were no initial or delayed AEs reported. Thirty-five patients (97.2%) were deceased at the time of analysis with a median 10.3 months of follow-up (range, 3.1-63.9). OS at 6 months and 12 months was 78% and 44%, respectively. The median OS was 10.4 months (range, 2.7-68). Among patients with stage III unresectable disease, 4 (20%) were downstaged and underwent an R0 resection. Conclusions: Our study suggests the feasibility, safety, and potential efficacy of gemcitabine EUS-FNI for PC. Additional data are needed to verify these observations and to determine the potential role relative to conventional multimodality therapy.

Original languageEnglish (US)
JournalGastrointestinal Endoscopy
DOIs
StateAccepted/In press - Jul 21 2016

Fingerprint

gemcitabine
Pancreatic Neoplasms
Needles
Injections
Survival
Feasibility Studies
Therapeutics
Tertiary Care Centers
Prospective Studies
Safety
Drug Therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. / Levy, Michael J.; Alberts, Steven Robert; Bamlet, William R.; Burch, Patrick A.; Farnell, Michael B.; Gleeson, Ferga C.; Haddock, Michael; Kendrick, Michael L.; Oberg, Ann L; Petersen, Gloria M; Takahashi, Naoki; Chari, Suresh T.

In: Gastrointestinal Endoscopy, 21.07.2016.

Research output: Contribution to journalArticle

Levy, Michael J. ; Alberts, Steven Robert ; Bamlet, William R. ; Burch, Patrick A. ; Farnell, Michael B. ; Gleeson, Ferga C. ; Haddock, Michael ; Kendrick, Michael L. ; Oberg, Ann L ; Petersen, Gloria M ; Takahashi, Naoki ; Chari, Suresh T. / EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. In: Gastrointestinal Endoscopy. 2016.
@article{38404822ff374ee695c8412db395001f,
title = "EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer",
abstract = "Background and Aims: Among the greatest hurdles to pancreatic cancer (PC) therapy is the limited tissue penetration of systemic chemotherapy because of tumor desmoplasia. The primary study aim was to determine the toxicity profile of EUS-guided fine-needle injection (EUS-FNI) with gemcitabine. Secondary endpoints included the ability to disease downstage leading to an R0 resection and overall survival (OS) at 6 months, 12 months, and 5 years after therapy. Methods: In a prospective study from a tertiary referral center, gemcitabine (38 mg/mL) EUS-FNI was performed in patients with PC before conventional therapy. Initial and delayed adverse events (AEs) were assessed within 72 hours and 4 to 14 days after EUS-FNI, respectively. Patients were followed for ≥5 years or until death. Results: Thirty-six patients with stage II (n = 3), stage III (n = 20), or stage IV (n = 13) disease underwent gemcitabine EUS-FNI with 2.5 mL (.7-7.0 mg) total volume of injectate per patient. There were no initial or delayed AEs reported. Thirty-five patients (97.2{\%}) were deceased at the time of analysis with a median 10.3 months of follow-up (range, 3.1-63.9). OS at 6 months and 12 months was 78{\%} and 44{\%}, respectively. The median OS was 10.4 months (range, 2.7-68). Among patients with stage III unresectable disease, 4 (20{\%}) were downstaged and underwent an R0 resection. Conclusions: Our study suggests the feasibility, safety, and potential efficacy of gemcitabine EUS-FNI for PC. Additional data are needed to verify these observations and to determine the potential role relative to conventional multimodality therapy.",
author = "Levy, {Michael J.} and Alberts, {Steven Robert} and Bamlet, {William R.} and Burch, {Patrick A.} and Farnell, {Michael B.} and Gleeson, {Ferga C.} and Michael Haddock and Kendrick, {Michael L.} and Oberg, {Ann L} and Petersen, {Gloria M} and Naoki Takahashi and Chari, {Suresh T}",
year = "2016",
month = "7",
day = "21",
doi = "10.1016/j.gie.2016.11.014",
language = "English (US)",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer

AU - Levy, Michael J.

AU - Alberts, Steven Robert

AU - Bamlet, William R.

AU - Burch, Patrick A.

AU - Farnell, Michael B.

AU - Gleeson, Ferga C.

AU - Haddock, Michael

AU - Kendrick, Michael L.

AU - Oberg, Ann L

AU - Petersen, Gloria M

AU - Takahashi, Naoki

AU - Chari, Suresh T

PY - 2016/7/21

Y1 - 2016/7/21

N2 - Background and Aims: Among the greatest hurdles to pancreatic cancer (PC) therapy is the limited tissue penetration of systemic chemotherapy because of tumor desmoplasia. The primary study aim was to determine the toxicity profile of EUS-guided fine-needle injection (EUS-FNI) with gemcitabine. Secondary endpoints included the ability to disease downstage leading to an R0 resection and overall survival (OS) at 6 months, 12 months, and 5 years after therapy. Methods: In a prospective study from a tertiary referral center, gemcitabine (38 mg/mL) EUS-FNI was performed in patients with PC before conventional therapy. Initial and delayed adverse events (AEs) were assessed within 72 hours and 4 to 14 days after EUS-FNI, respectively. Patients were followed for ≥5 years or until death. Results: Thirty-six patients with stage II (n = 3), stage III (n = 20), or stage IV (n = 13) disease underwent gemcitabine EUS-FNI with 2.5 mL (.7-7.0 mg) total volume of injectate per patient. There were no initial or delayed AEs reported. Thirty-five patients (97.2%) were deceased at the time of analysis with a median 10.3 months of follow-up (range, 3.1-63.9). OS at 6 months and 12 months was 78% and 44%, respectively. The median OS was 10.4 months (range, 2.7-68). Among patients with stage III unresectable disease, 4 (20%) were downstaged and underwent an R0 resection. Conclusions: Our study suggests the feasibility, safety, and potential efficacy of gemcitabine EUS-FNI for PC. Additional data are needed to verify these observations and to determine the potential role relative to conventional multimodality therapy.

AB - Background and Aims: Among the greatest hurdles to pancreatic cancer (PC) therapy is the limited tissue penetration of systemic chemotherapy because of tumor desmoplasia. The primary study aim was to determine the toxicity profile of EUS-guided fine-needle injection (EUS-FNI) with gemcitabine. Secondary endpoints included the ability to disease downstage leading to an R0 resection and overall survival (OS) at 6 months, 12 months, and 5 years after therapy. Methods: In a prospective study from a tertiary referral center, gemcitabine (38 mg/mL) EUS-FNI was performed in patients with PC before conventional therapy. Initial and delayed adverse events (AEs) were assessed within 72 hours and 4 to 14 days after EUS-FNI, respectively. Patients were followed for ≥5 years or until death. Results: Thirty-six patients with stage II (n = 3), stage III (n = 20), or stage IV (n = 13) disease underwent gemcitabine EUS-FNI with 2.5 mL (.7-7.0 mg) total volume of injectate per patient. There were no initial or delayed AEs reported. Thirty-five patients (97.2%) were deceased at the time of analysis with a median 10.3 months of follow-up (range, 3.1-63.9). OS at 6 months and 12 months was 78% and 44%, respectively. The median OS was 10.4 months (range, 2.7-68). Among patients with stage III unresectable disease, 4 (20%) were downstaged and underwent an R0 resection. Conclusions: Our study suggests the feasibility, safety, and potential efficacy of gemcitabine EUS-FNI for PC. Additional data are needed to verify these observations and to determine the potential role relative to conventional multimodality therapy.

UR - http://www.scopus.com/inward/record.url?scp=85009210458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009210458&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2016.11.014

DO - 10.1016/j.gie.2016.11.014

M3 - Article

C2 - 27889543

AN - SCOPUS:85009210458

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

ER -